Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia

Relapsed/refractory (rel/ref) acute myeloid leukemia (AML) has a very high mortality rate. At present, hematopoietic stem cell transplantation (HSCT) is the most effective treatment for rel/ref AML. The remission of the primary disease before HSCT is crucial for the transplantation to be effective. Therefore, it is critical to choose a suitable type of chemotherapy before HSCT. Here, we recorded the outcomes of high-throughput drug sensitivity screening (HDS) in children with rel/ref AML. Thirty-seven pediatric rel/ref AML patients who received HDS from September 2017 until July 2021 were analyzed retrospectively. Most of the patients (24 patients, 64.9%) had adverse cytogenetics. Two patients had rel/ref AML with central nervous system leukemia. The complete remission (CR) rate was 67.6%. Eight patients developed IV grade bone marrow suppression. Twenty-three patients (62.2%) underwent HSCT. The 3-year overall survival (OS) and EFS rates were 45.9% and 43.2%, respectively. Infection in the myelosuppression stage was the main cause of death. The outcome of HDS was superior to the commonly reported rates. These results suggest that HDS may be a novel treatment option for pediatric patients with rel/ref AML, and it is a promising transitional regimen prior to HSCT.

[1]  Ping Wang,et al.  [Clinical Analysis of Pediatric Acute Myeloid Leukemia with CCLG-AML 2015 Regimen]. , 2022, Zhongguo shi yan xue ye xue za zhi.

[2]  Liang Wang,et al.  Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia , 2021, Molecular and clinical oncology.

[3]  J. Serody,et al.  Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. , 2021, Blood cancer discovery.

[4]  Xiaojuan Chen,et al.  Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy , 2021, Cancer medicine.

[5]  R. Taplitz,et al.  Updates in infection risk and management in acute leukemia. , 2020, Hematology. American Society of Hematology. Education Program.

[6]  S. Shen,et al.  The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China , 2020, Pediatric hematology and oncology.

[7]  C. Nair,et al.  Infection at diagnosis—a unique challenge in acute myeloid leukemia treatment in developing world , 2020, Supportive Care in Cancer.

[8]  R. Rau,et al.  The genomics of acute myeloid leukemia in children , 2020, Cancer and Metastasis Reviews.

[9]  Diana Lagana,et al.  Bloodstream infections in neutropenic patients with haematological malignancies. , 2020, Infection, disease & health.

[10]  R. Aplenc,et al.  Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. , 2019, Current opinion in pediatrics.

[11]  Jun Wang,et al.  High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing. , 2019, Biomaterials.

[12]  M. Viana,et al.  Cytogenetic abnormalities, WHO classification, and evolution of children and adolescents with acute myeloid leukemia , 2019, Hematology, transfusion and cell therapy.

[13]  Y. Nakazawa,et al.  Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia , 2018, Bone Marrow Transplantation.

[14]  A. Mansour,et al.  Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival , 2018, Jornal de pediatria.

[15]  Beth Wilmot,et al.  Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.

[16]  F. Chong,et al.  Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time , 2017, Nature Communications.

[17]  J. Cortes,et al.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.

[18]  G. Lucchini,et al.  Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience , 2015, Bone Marrow Transplantation.

[19]  S. Jaiswal,et al.  Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  P. Marik,et al.  A Descriptive Study , 2015 .

[21]  S. Raimondi,et al.  Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Hong-guo Zhao,et al.  [Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults]. , 2014, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[23]  S. Davies,et al.  Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. , 2014, Blood.

[24]  Krister Wennerberg,et al.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.

[25]  E. Steliarova-Foucher,et al.  New policies to address the global burden of childhood cancers. , 2013, The Lancet. Oncology.

[26]  T. Renaud,et al.  Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments , 2013, Pediatric Drugs.

[27]  D. Reinhardt,et al.  Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report , 2012, Leukemia.

[28]  R. Rihani,et al.  Outcome of childhood acute lymphoblastic leukemia in Jordan , 2011, Pediatric blood & cancer.

[29]  Eva Steliarova-Foucher,et al.  Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. , 2008, The Lancet. Oncology.

[30]  R. Schlenk,et al.  Significance of age in acute myeloid leukemia patients younger than 30 years , 2008, Cancer.

[31]  R. Hanada,et al.  Repetitive cycles of high‐dose cytarabine are effective for childhood acute myeloid leukemia: Long‐term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group , 2007, Pediatric blood & cancer.

[32]  C. Pui,et al.  Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.

[33]  U. Creutzig,et al.  Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.

[34]  G. Specchia,et al.  FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience , 2003, Annals of Hematology.

[35]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[36]  P. Huxley.  A UK experience. , 1998, Canadian journal of community mental health = Revue canadienne de sante mentale communautaire.

[37]  Unión,et al.  Bortezomib/Cyclophosphamide/Dexamethasone Regimen , 2020, Definitions.